Skip to main content

Market access for medical technologies in Switzerland

A brief overview of key market access pathways and challenges for medical devices, in-vitro diagnostic tests in Switzerland

fghjh

Key topics

There are two key themes describing market access for medical technologies in Switzerland: 

  • Reimbursement: payment mechanism via DRG system, add-on reimbursement via ZE in hospital settings; payment via TARMED (soon to be replaced by TARDOC) catalog in out-patient settings
  • Funding: coverage decisions within the statutory health insurance by the Federal Office of Public Health

There is no health technology assessment challenge in Switzerland. HTA is integrated into funding decision-making.

Switzerland has one innovative payment scheme for medical technologies (Provisional reimbursement of medical procedures). 

sdf

Reimbursement

Reimbursement for hospital procedures is made solely via the SwissDRG system. All cases of hospitalization with at least one overnight stay are reimbursed via DRG. Day cases and outpatient care are completely separate from hospital care provisions and currently reimbursed via a fee-for-service model using the TARMED catalog. However, in 2026, the TARMED catalog is expected to be replaced by the TARDOC catalog for outpatient procedures and the outpatient flat-rates system for interventions performed in day case settings).

The DRG system has the following components:

Diagnosis-related groups

  • DRGs are determined by the combination of a procedure code (CHOP) and a diagnosis code (ICD-10-GM). CHOP nomenclature is maintained by the Federal Statistics Office (BFS/UFS) and released annually
  • The base rate is determined nationally, and the Cantons have to approve and adopt it. In case they do not adopt it, the Cantons may set their own base rate (rarely the case) 

Add-on reimbursement (Zusatzentgelt, ZE)

  • Add-on reimbursement is provided for expensive devices, procedures, and drugs
    Tariff is typically determined on the national level by the administrator of the DRG system, SwissDRG

The SwissDRG system is approved annually.

Procedures performed in out-patient and day case settings are reimbursed via a fee-for-service mechanism via the TARMED catalog (soon to be replaced).

sdxc

Funding

In the inpatient sector, medical devices/procedures are automatically reimbursed according to the so-called “principle of trust” unless they are questioned by a stakeholder of the system (typically insurance companies). In this case, the Federal Office for Public Health (FOPH) evaluates the questioned device/procedure and develops a coverage decision. 

dcvd

Specifics for IVD tests

In-vitro diagnostic tests are reimbursed using a fee-for-service mechanism via the List of Analyses (Annex 3 of the Healthcare Benefit Ordinance, KLV/OPre) in out-patient settings.

MTRC has experience with more than 173 projects in Switzerland

News and insights

New outpatient procedures received analogous coding in August 2026 in Switzerland

In the Swiss outpatient reimbursement system, new procedures that currently lack a specific LKAAT procedure code can receive analogous coding, thereby providing temporary reimbursement. In August 2026, the Organization for Outpatient Physician Tariffs, responsible for developing and maintaining the Swiss outpatient reimbursement system, updated its list of analogous and reserve code assignments, adding several imaging and surgical procedures.

The 2027 version of the Swiss Classification of Surgical Procedures

On July 30, 2026, the Swiss Federal Statistical Office (OFS) released the systematic version of the Swiss Classification of Surgical Interventions (CHOP) for 2027. The CHOP classification is now available in German and will come into force on January 1, 2027. Multiple new procedure codes were introduced in various fields, including digital therapeutics, endoscopy, gastrointestinal, obstetrics and gynecology, nephrology and urology, men's health, neuromodulation, orthopedics, and peripheral vascular.

Updates in the coverage of medical services in Switzerland in July 2026

On June 9, 2026, the Swiss Federal Office of Public Health published changes to the Healthcare Benefit Ordinance (KLV/OPre), which determines coverage of medical services in Switzerland. The nearest changes will take effect on July 1, 2026, and include the introduction of the first-trimester preeclampsia screening and adjustment of the tariffs for the highest-grossing laboratory analyses (Annex 3 KLV), changes in reimbursement conditions for medical aids via the List of Medical Aids MiGel (Annex 2 KLV), as well as the expansion of the outpatient-before-inpatient policy (Annex 1a KLV) and update of coverage decisions on the List of explicitly evaluated services (Annex 1 KLV).

Get in touch

Contact us to discuss your needs and learn about our services